Keryx Biopharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


BOSTON, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ: KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced it will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11, 2016 at 9:30 a.m. PST (12:30 p.m. PST).

A live audio webcast of both the presentation and immediately following breakout session will be accessible from Keryx's website at http://investors.keryx.com within the Investor Relations section under the "webcasts and presentations" page. An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation and breakout session.

About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in Boston and New York, is focused on bringing innovative therapies to market for patients with renal disease. In December 2014, the company launched its first FDA-approved product, Auryxia™ (ferric citrate) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex) for the control of hyperphosphatemia in adults with non-dialysis and dialysis-dependent chronic kidney disease. For more information about Keryx, please visit www.keryx.com.

KERYX CONTACT:Lora PikeSenior Director, Investor RelationsT: 617-466-3511lora.pike@keryx.com


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Press Releases